Taconic Biosciences Adds New Humanized Immune System (HIS) Model to Its Portfolio For Immuno-Oncology Research
New huNOG-EXL EA Model Extends Study Windows Significantly RENSSELAER, N.Y., Jan. 18, 2022 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery